Protein tyrosine kinase inhibitors in cancer therapy

被引：5

作者：

Boutayeb, S. ^{[1
]}

Zakkouri, F. Z. ^{[1
]}

Aitelhaj, M. ^{[1
]}

Mesmoudi, M. ^{[1
]}

Boutayeb, A. ^{[2
]}

Boutayeb, W. ^{[2
]}

Mrabti, H. ^{[1
]}

Errihani, H. ^{[1
]}

机构：

[1] CHU Ibn Slum, Inst Natl Oncol, Serv Oncol Med, Rabat, Morocco

[2] Univ Mohammed 1, Fac Sci, Unite Biostat, Oujda, Morocco

来源：

PATHOLOGIE BIOLOGIE | 2012年 / 60卷 / 04期

关键词：

Tyrosine kinase inhibitor; Cancer; Signal transduction; CELL LUNG-CANCER; PHASE-III; IMATINIB MESYLATE; DOUBLE-BLIND; VANDETANIB; SUNITINIB; ERLOTINIB; 1ST-LINE;

D O I：

10.1016/j.patbio.2012.05.007

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The tyrosine kinase inhibitors (TKI) are small molecules of low molecular weight that inhibit tyrosine kinases, enzymes responsible for the activation of signal transduction cascades. Currently, a number of TKI received approval in various cancers, while others are in clinical development process: TKI are specifically clinically active when they target a tyrosine kinase (TK) with constitutional activity subsequent to a mutation, being then a master-gene driving transformation and tumour progression. Already, this drug-family provides a major therapeutic weapon against cancer. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：229 / 233

页数：5

共 50 条

[1] Tyrosine kinase inhibitors in cancer therapy
Madhusudan, S
Ganesan, TS
CLINICAL BIOCHEMISTRY, 2004, 37 (07) : 618 - 635
[2] Tyrosine kinase inhibitors as cancer therapy
Nichols, GL
CANCER INVESTIGATION, 2003, 21 (05) : 758 - 771
[3] Tyrosine kinase inhibitors in cancer therapy
Eckhardt, S.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (05) : 461 - 461
[4] Role of tyrosine kinase inhibitors in cancer therapy
Arora, A
Scholar, EM
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 971 - 979
[5] Protein tyrosine kinase inhibitors in cancer treatment
Traxler, PM
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (06) : 571 - 588
[6] New tyrosine kinase and EGFR inhibitors in cancer therapy
Rottlaender, D.
Reda, S.
Motloch, L. J.
Hoppe, U. C.
INTERNIST, 2011, 52 (10): : 1245 - +
[7] Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, LK
Slamon, D
Ullrich, A
CANCER CELL, 2002, 1 (02) : 117 - 123
[8] Antiangiogenic therapy of cancer by multitargeted tyrosine kinase inhibitors
Agata, Naoki
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 40P - 40P
[9] Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
Russo, Eleonora
Spallarossa, Andrea
Tasso, Bruno
Villa, Carla
Brullo, Chiara
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
[10] Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer
Antonelli, Alessandro
Fallahi, Poupak
Ulisse, Salvatore
Ferrari, Silvia Martina
Mazzi, Valeria
Di Domenicantonio, Andrea
Miccoli, Paolo
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2015, 2 (02) : 135 - 142

← 1 2 3 4 5 →